迪哲医药高管集中减持：董事长刚套现1亿，两位副总又宣布千万减持

Core Viewpoint - Recent announcements from Dize Pharmaceutical indicate significant insider selling, with the chairman and two vice presidents reducing their stakes in the company due to personal financial needs [1][6]. Insider Selling - On May 19, Dize Pharmaceutical announced that Vice President and Chief Commercial Officer Wu Qingyi plans to sell up to 302,054 shares, representing no more than 0.0657% of the total share capital, while Vice President Zhang Shiying intends to sell up to 16,000 shares, accounting for no more than 0.0035% of the total share capital [1][2]. - The selling period is set from June 24, 2025, to September 23, 2025, with prices determined by market conditions during the selling period [1]. Shareholding Information - As of the announcement date, Wu Qingyi holds 1,208,217 shares, which is 0.2630% of the total share capital, while Zhang Shiying holds 65,000 shares, or 0.0141% of the total share capital [2]. Market Performance - As of May 20, Dize Pharmaceutical's stock price increased by 1.91%, closing at ¥57.53, with a total market capitalization of ¥26.43 billion [3][4]. - The estimated total value of the shares to be sold by the two vice presidents is approximately ¥18.29 million [3]. Company Background - Dize Pharmaceutical was established on October 27, 2017, with a registered capital of ¥416 million, focusing on the research and wholesale of chemical drugs and biological medicines [7]. - The major shareholder is AstraZeneca AB, holding 26.21% of the company [7]. Financial Performance - In 2024, Dize Pharmaceutical reported revenues of ¥360 million, a year-on-year increase of 294.24%, but incurred a net loss of approximately ¥846 million, compared to a loss of ¥1.108 billion in the previous year [7]. - For the first quarter of 2025, the company achieved revenues of ¥160 million, a 96.32% year-on-year increase, with a net loss of approximately ¥193 million, compared to a loss of ¥224 million in the same period last year [7].